Drugs / alpha-methyl-paratyrosine
alpha-methyl-paratyrosine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02152670 | May → Jun 2014 | cocaine dependence | Yale University | Terminated | No outcome recorded |
| — | NCT02179814 | Feb 2012 → May 2019 | bulimia nervosa | University of Bern | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha Methyl Para Tyrosine | “alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours” NCT02179814 ↗ |
| Known as | AMPT | “alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours” NCT02179814 ↗1“Drug: Alpha Methyl Para Tyrosine (AMPT)” NCT02152670 ↗ |
| Known as | Demser | “alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours” NCT02179814 ↗ |
| Action | Inhibit | “This medication is a tyrosine hydroxylase inhibitor” NCT02179814 ↗ |
| Route | Oral | “oral administration of alpha-methyl-paratyrosine (AMPT)” NCT02179814 ↗ |